The last 6 months have been incredibly busy for the Acorai team, executing with full pace on our product development and global CAPTURE-HF study, while continuing to generate awareness and impressing judges and audiences alike, showcasing the potential of our technology. Below is a selection of recent achievements by the team:
CAPTURE-HF Clinical Study Phase 1 Completed
We are thrilled to announce the successful completion of the first Phase of the CAPTURE-HF clinical study, a monumental milestone in our mission to revolutionize heart failure treatment. A special thanks to all of the clinical sites supporting the completion of the study!
Acorai Accepted into Medtech Innovator AHA Program
Acorai has been accepted into the prestigious Medtech Innovator American Heart Association program. This highly competitive accelerator is designed to support promising medical technology startups. Through the program, we will gain invaluable mentorship, support, industry connections and exposure.
Triumph at the EIT Health Catapult
Acorai was awarded the “most promising healthtech startup” by EIT Health Catapult, and also won 3 of 4 industry prizes during the event (AWS, AstraZeneca & Lusíadas Saúde)!
Acorai Presents Pilot Study Data
In May, Acorai’s CSO Matthew presented more data from our Pilot study at the HFA conference in Lisbon, where early feasibility data indicates that the device can accurately estimate ICPs, CO, and EF. See the full poster to learn more here.
FDA BDD Total Life Cycle Advisory Program (TAP)
Acorai continues to work closely with the FDA through the Total Life Cycle Advisory Program (TAP), aligning on study outcomes, device performance and understanding the regulatory pathway to approval.
Thank you for your continued support and belief in Acorai’s mission. Together, we are making a significant impact in the fight against heart failure.
Warmest regards, The Acorai Team.